Moderna, Inc.MRNA
What Moderna, Inc. does.
Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more.
With a global team and a unique culture, driven by our values and mindsets, our mission is to deliver the greatest possible impact to people through mRNA medicines.
We currently have three commercial products—Spikevax and mNEXSPIKE (our COVID vaccines) and mRESVIA (our vaccine against respiratory syncytial virus (RSV)). mNEXSPIKE, which we launched commercially in the third quarter of 2025, is now our leading product in the U.S. retail channel. In 2025, we achieved total revenue of $1.9 billion, largely from sales of our COVID vaccines.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $803.0M | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |
| Net income | -$747.0M | $12.2B | $8.4B | -$4.7B | -$3.6B | -$2.8B |
| Free cash flow | $2.0B | $13.3B | $4.6B | -$3.8B | -$4.1B | -$2.1B |
More on MRNA.
- Moderna, Inc. summary
- Moderna, Inc. financial statements
- Moderna, Inc. key metrics
- Moderna, Inc. health scores and style box
- Moderna, Inc. earnings
- Moderna, Inc. dividends
- Moderna, Inc. valuation
- Moderna, Inc. ownership and insiders
- Moderna, Inc. peers
Figures from Moderna, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.